<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48603">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01916928</url>
  </required_header>
  <id_info>
    <org_study_id>MedStarWHC-OB</org_study_id>
    <nct_id>NCT01916928</nct_id>
  </id_info>
  <brief_title>The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage</brief_title>
  <official_title>The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Research Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women presenting to Washington Hospital Center with fetal loss would be offered
      participation in the study.  The objective is to determine if ccffDNA obtained from maternal
      blood is present in the setting of missed abortion or fetal demise.

      The investigators primary hypothesis is that cell free fetal DNA will be present in maternal
      blood in the presence of a failed pregnancy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The presence or absence of cell free fetal DNA in maternal blood in the setting of a failed pregnancy.</measure>
    <time_frame>During initial presentation for treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The accuracy of ccffDNA compared to genetic information obtained from amniocentesis, chorionic villus sampling, fetal, or placental tissue.</measure>
    <time_frame>3-4 weeks after specimen processing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Circulating Cell Free Fetal DNA</condition>
  <condition>Intrauterine Fetal Demise</condition>
  <condition>Miscarriage</condition>
  <arm_group>
    <arm_group_label>Miscarriage</arm_group_label>
    <description>Women with fetal death prior to 20 weeks gestation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intrauterine Fetal Demise</arm_group_label>
    <description>Women presenting with stillbirth, defined as fetal death occurring after 20 weeks gestation.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood collection will consist of two ten milliliters samples of whole blood in the cffDNA
      STRECK tube.  Plasma will be retained for analysis of circulating cell free fetal DNA.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women presenting to Washington Hospital Center with fetal loss would be offered DNA
        sequencing of cell free fetal DNA from maternal blood in addition to the standard workup
        for fetal demise and miscarriage as deemed appropriate by the patient's care provider.
        Only women with sonographic evidence of products of conception in-utero will be offered
        enrollment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women diagnosed with Intrauterine fetal demised or missed abortion

        Exclusion Criteria:

          -  Patients diagnosed with threatened abortion with cardiac activity present

          -  Patients with IUFD who have delivered the fetus (the induction process may already be
             in process, however, the fetus and placenta must be in situ at the time of blood
             sampling)

          -  Patients with known genetic abnormalities or mental retardation as a result of
             chromosomal abnormalities 13, 18, 21, or sex chromosomes.

          -  Children under the age of 18

          -  Patients not fluent in or unable to consent to the study in English
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rita W Driggers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medstar Washington Hospital Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rita W. Driggers, MD</last_name>
    <phone>202-877-7127</phone>
    <email>Rita.W.Driggers@medstar.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cecily A Clark-Ganheart, MD</last_name>
    <phone>2692092048</phone>
    <email>ganheartmd@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medstar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecily A Clark-Ganheart, MD</last_name>
      <phone>202-801-2186</phone>
      <email>cecily.a.clark-ganheart@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Rita W Driggers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cecily A Clark-Ganheart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nagaishi M, Yamamoto T, Iinuma K, Shimomura K, Berend SA, Knops J. Chromosome abnormalities identified in 347 spontaneous abortions collected in Japan. J Obstet Gynaecol Res. 2004 Jun;30(3):237-41.</citation>
    <PMID>15210050</PMID>
  </reference>
  <reference>
    <citation>Baena N, Guitart M, Ferreres JC, Gabau E, Corona M, Mellado F, Egozcue J, Caball√≠n MR. Fetal and placenta chromosome constitution in 237 pregnancy losses. Ann Genet. 2001 Apr-Jun;44(2):83-8.</citation>
    <PMID>11522246</PMID>
  </reference>
  <reference>
    <citation>Kyle PM, Sepulveda W, Blunt S, Davies G, Cox PM, Fisk NM. High failure rate of postmortem karyotyping after termination for fetal abnormality. Obstet Gynecol. 1996 Nov;88(5):859-62.</citation>
    <PMID>8885928</PMID>
  </reference>
  <reference>
    <citation>MacDorman MF, Kirmeyer S. Fetal and perinatal mortality, United States, 2005. Natl Vital Stat Rep. 2009 Jan 28;57(8):1-19.</citation>
    <PMID>19294965</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 5, 2013</lastchanged_date>
  <firstreceived_date>August 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medstar Research Institute</investigator_affiliation>
    <investigator_full_name>Cecily A. Clark-Ganheart MD</investigator_full_name>
    <investigator_title>Director of Maternal Fetal Medicine</investigator_title>
  </responsible_party>
  <keyword>Circulating cell free fetal DNA</keyword>
  <keyword>Intrauterine fetal demise</keyword>
  <keyword>Miscarriage</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
